According to European Society for Medical Oncology (ESMO) guideline (30) SSAs is recommended as first-line therapy for tumour growth control in advanced, slowly-growing SSTR-positive gastrointestinal and pNETs with Ki-67 up to 10%. Here, MKI67 is linked to neoplasm.